K. Sherman, S. Rouster, R. Chung, and N. Rajicic, Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group, Clinical Infectious Diseases, vol.34, issue.6, pp.831-837, 2002.
DOI : 10.1086/339042

M. Sulkowski, R. Moore, S. Mehta, R. Chaisson, and D. Thomas, Hepatitis C and Progression of HIV Disease, JAMA, vol.288, issue.2, pp.199-206, 2002.
DOI : 10.1001/jama.288.2.199

D. Thomas, D. Vlahov, L. Solomon, S. Cohn, E. Taylor et al., Correlates of Hepatitis C Virus Infections among Injection Drug Users, Medicine, vol.74, issue.4, pp.212-220, 1995.
DOI : 10.1097/00005792-199507000-00005

E. Rosenthal, M. Poiree, C. Pradier, C. Perronne, D. Salmon-ceron et al., Mortality due to hepatitis C-related liver disease in HIV-infected patients in France, AIDS, issue.12, pp.171803-1809, 2001.

V. Soriano, L. Martin-carbonero, J. Garcia-samaniego, and M. Puoti, Mortality Due to Chronic Viral Liver Disease among Patients Infected with Human Immunodeficiency Virus, Clinical Infectious Diseases, vol.33, issue.10, pp.1793-1795, 2001.
DOI : 10.1086/323009

K. Lindahl, L. Stahle, A. Bruchfeld, and R. Schvarcz, High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C, Hepatology, vol.49, issue.2, pp.275-279, 2005.
DOI : 10.1002/hep.20563

A. Rendon, M. Nunez, M. Romero, P. Barreiro, L. Martin-carbonero et al., Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.39, issue.4, pp.401-405, 2005.
DOI : 10.1097/01.qai.0000170034.90438.68

M. Crespo, L. Pou, J. Esteban, V. Falco, E. Ribera et al., Pahissa A: Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients, Antivir Ther, issue.8, pp.121217-1223, 2007.

J. Jen, M. Laughlin, C. Chung, S. Heft, M. Affrime et al., Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models, Clinical Pharmacology & Therapeutics, vol.72, issue.4, pp.349-361, 2002.
DOI : 10.1067/mcp.2002.127112

J. Jen, P. Glue, S. Gupta, D. Zambas, and G. Hajian, Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C, Therapeutic Drug Monitoring, vol.22, issue.5, pp.555-565, 2000.
DOI : 10.1097/00007691-200010000-00010

S. Larrat, F. Stanke-labesque, A. Plages, J. Zarski, G. Bessard et al., Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C, Antimicrobial Agents and Chemotherapy, vol.47, issue.1, pp.124-129, 2003.
DOI : 10.1128/AAC.47.1.124-129.2003

J. Wade, E. Snoeck, F. Duff, M. Lamb, and K. Jorga, Pharmacokinetics of ribavirin in patients with hepatitis C virus, British Journal of Clinical Pharmacology, vol.43, issue.6, pp.710-714, 2006.
DOI : 10.1097/00007691-200212000-00004

A. Bruchfeld, K. Lindahl, R. Schvarcz, and L. Stahle, Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic Analysis, Therapeutic Drug Monitoring, vol.24, issue.6, pp.701-708, 2002.
DOI : 10.1097/00007691-200212000-00004

H. Dahari, M. Markatou, M. Zeremski, I. Haller, R. Ribeiro et al., Talal AH: Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin, pp.4723-4753, 2007.

V. Loustaud-ratti, A. S. Rousseau, A. Hubert, I. Sauvage, F. Marquet et al., Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C, Hepatology, vol.16, issue.5, pp.471453-1461, 2008.
DOI : 10.1002/hep.22217

URL : https://hal.archives-ouvertes.fr/hal-00406823

M. Arab-alameddine, A. Fayet-mello, R. Lubomirov, M. Neely, J. Di-iulio et al., Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals, Antimicrobial Agents and Chemotherapy, vol.56, issue.6, pp.562959-2966
DOI : 10.1128/AAC.05424-11

F. Sauvage, F. Stanke-labesque, M. Gagnieu, J. Jourdil, G. Babany et al., Feasibility of Ribavirin Therapeutic Drug Monitoring in Hepatitis C, Therapeutic Drug Monitoring, vol.31, issue.3, pp.31374-381, 2009.
DOI : 10.1097/FTD.0b013e3181a665e3

URL : https://hal.archives-ouvertes.fr/inserm-00369970

A. Marucco, D. Gonzalez-de-requena, D. Bonora, S. Tettoni, C. Bonasso et al., The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCVco-infected patients treated with ribavirin and pegylated interferon, J Antimicrob Chemother, issue.4, pp.61919-924, 2008.

S. Piedoux, E. Monnet, L. Piroth, D. Montange, B. Royer et al., Relative impact of ribavirin monitoring and HIV coinfectiononsustainedvirologicalresponseinpatientswithchronic hepatitis C, Antivir Ther, issue.8, pp.161317-1326, 2011.

M. Sulkowski and Y. Benhamou, Therapeutic issues in HIV/HCV-coinfected patients, Journal of Viral Hepatitis, vol.71, issue.3, pp.371-386, 2007.
DOI : 10.1053/jhep.2002.36502

C. Souvignet, M. Maynard, M. Gagnieu, and C. Trepo, Ribavirin in combination therapy for HCV chronic infection in HIV patients: How to win the war after winning the first battle?, Journal of Hepatology, vol.47, issue.1, pp.1-3, 2007.
DOI : 10.1016/j.jhep.2007.04.001

F. Carrat, F. Bani-sadr, S. Pol, E. Rosenthal, F. Lunel-fabiani et al., Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>, JAMA, vol.292, issue.23, pp.2922839-2848, 2004.
DOI : 10.1001/jama.292.23.2839

M. Nunez, C. Miralles, M. Berdun, E. Losada, K. Aguirrebengoa et al., Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial, AIDS Research and Human Retroviruses, vol.23, issue.8, pp.972-982, 2007.
DOI : 10.1089/aid.2007.0011

A. Lafeuillade, G. Hittinger, and S. Chadapaud, Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection, The Lancet, vol.357, issue.9252, pp.280-281, 2001.
DOI : 10.1016/S0140-6736(00)03618-7

A. Moreno, C. Quereda, L. Moreno, M. Perez-elias, A. Muriel et al., High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin, Antivir Ther, vol.9, issue.1, pp.133-138, 2004.

V. Soriano, M. Puoti, M. Sulkowski, A. Cargnel, Y. Benhamou et al., Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV???HIV International Panel, AIDS, vol.21, issue.9, pp.1073-1089, 2007.
DOI : 10.1097/QAD.0b013e3281084e4d